Key Insights

Highlights

Treatment Research

13 treatments under study, led by Fludarabine

Research Leaders

5 sponsors active, led by Fondazione IRCCS San Gerardo dei Tintori

Related Conditions

Often studied with 15 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Phase 1 (2)
Phase 1/2 (1)

Trial Status

Recruiting3

Clinical Trials (3)

Showing 3 of 3 trials
NCT07877610Phase 1/2Recruiting

CARCIK CD123/33 for Refractory/Relapsed AML and BPDCN in Children and Adults

NCT04318678Phase 1Recruiting

CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

NCT05476770Phase 1Recruiting

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Showing all 3 trials

Research Network

Common Treatments

  • Fludarabine2
  • Carcik Cd12333 Infusion1
  • Cd123car T1
  • Tagraxofusp1
  • Cyclophosphamide1

Active Sponsors

  • Fondazione IRCCS San Gerardo dei Tintori1
  • Therapeutic Advances in Childhood Leukemia Consortium1
  • St. Jude Children's Research Hospital1
  • Fondazione Tettamanti1
  • Fondazione Matilde Tettamanti Menotti De Marchi Onlus1

Top Investigators

Related Conditions

  • Aml Acute Myeloid Leukemia1
  • Lymphoblastic Lymphoma1
  • Amlmds1
  • Lymphoma Tcell1
  • Hodgkin Lymphoma1

Activity Timeline